Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!
Data: Yahoo Finance; Chart: Axios Visuals

Moderna's stock soared 9% on Monday following a new federal grant and the official start of a late-stage trial for the company's coronavirus vaccine.

The bottom line: Moderna now has received almost $1 billion in taxpayer funds to help develop a vaccine that is tied to the work of federal scientists, and the stock market reactions signal that investors think they'll reap a lot of the reward if the vaccine is proven to work.

By the numbers: Moderna, which has no FDA-approved drugs on the market, is now valued at $31 billion.

  • The massive stock rally has paid off for executives. Moderna CEO Stéphane Bancel has sold $9 million worth of stock in July alone.

Go deeper

Updated 5 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Rae Cook/Axios

  1. Health: CDC expects new COVID surge starting this month — Coronavirus cases hit a seven-month low
  2. Politics: Federal judge overturns CDC's eviction moratorium — Why Biden's latest vaccine goal is his hardest yet.
  3. Vaccines: Moderna says its COVID booster shot shows promise against variants — U.S. will support waiving vaccine patents — Education secretary: All schools expected to be fully in-person this fall
  4. Economy: U.S. may have added more than 2 million jobs in April — A surge in youth unemployment.
  5. World: True COVID-19 death toll is double the official numbers, study finds — Countries testing J&J vaccine doses after contamination at Baltimore plant — Germany opposes Biden's support for waiving vaccine patents
  6. Variant tracker: Where different strains are spreading.
Dave Lawler, author of World
Nov 4, 2020 - World

Italy imposes regional lockdown as coronavirus cases spike

Prime Minister Giuseppe Conte (c) made the call. Photo: Antonio Masiello/Getty Images

Much of Italy will be placed under a strict lockdown as of Friday in the most drastic steps the country has taken to fight the coronavirus since it led the world into lockdown nearly eight months ago.

The big picture: Italy managed to keep the spread of the virus largely under control for months after a brutal first wave. But like much of Europe, it's currently recording unprecedented daily case counts and scrambling to avoid a return to overcrowded hospitals and climbing death tolls in the coming weeks.

Bryan Walsh, author of Future
Nov 4, 2020 - Health

Air pollution connected to higher COVID-19 death rates

Smokestacks in Florida. Photo: Getty Images

A new study of more than 3,000 counties in the U.S. finds a correlation between higher levels of particulate air pollution and higher death rates from COVID-19.

Why it matters: COVID-19 may be caused by the novel coronavirus, but the outcome of an infection is influenced by everything from age to race to the environment. Understanding the connection between disease and pollution can help us address those risks going forward.

You’ve caught up. Now what?

Sign up for Mike Allen’s daily Axios AM and PM newsletters to get smarter, faster on the news that matters.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!